RIGImmune reports new funding support from the Bill & Melinda Gates Foundation to advance the company’s RNA stem loop therapeutics platform for the treatment and adjuvancy of respiratory illnesses caused by RNA viruses.
“This new program-related investment from the Gates Foundation will enable RIGImmune to accelerate our efforts to develop effective treatments and potential vaccine adjuvants for influenza and other respiratory disease caused by RNA viruses,” said Susan Sobolov, Ph.D., president of RIGImmune.